Addressing a Common Misconception of Simple Additive and Cumulative Drug Inhibition: Multiple Weak Inhibitors of Common Metabolic Pathway Do Not Pose a Strong Interaction Risk!

The Journal of Clinical Pharmacology 2026 Open access

Read full text

Authors: Daniel Scotcher, Avijit Ghosh, Aleksandra Galetin, Amin Rostami‐Hodjegan

DOI: 10.1002/jcph.70154

Cited by: 0

Fields of Study & Subjects

Pharmacogenetics and Drug Metabolism Pharmaceutical Practices and Patient Outcomes Pharmacovigilance and Adverse Drug Reactions